KSI-301

Kodiak Sciences has successfully enrolled over 250 patients in its GLOW2 Phase 3 trial of tarcocimab tedromer for diabetic retinopathy, with topline data expected in Q1 2026.

Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.

A comprehensive analysis of global diabetic retinopathy clinical trials has been released, offering insights into trial distribution across G7 and E7 countries and various research phases.

Kodiak Sciences' tarcocimab, an anti-VEGF antibody biopolymer conjugate, is in Phase 3 trials for diabetic retinopathy and wet AMD.